Market Analysis on Benign Prostatic Hyperplasia Treatment Industry – Insights for Corporate Strategy and R&D
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Benign Prostatic Hyperplasia Treatment Market from 2024 to 2025?
In recent times, the market for benign prostatic hyperplasia treatment has witnessed significant growth. It is projected to increase from $8.23 billion in 2024 to $8.71 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.9%. Factors such as heightened awareness and screening initiatives, surge in the cases of BPH, enhanced consciousness about healthcare, betterment of healthcare infrastructure and an aging population have contributed to this growth during the historical period.
What Is the Projected Market Size of the Benign Prostatic Hyperplasia Treatment Market?
The market size for benign prostatic hyperplasia treatment is projected to experience significant expansion in the coming years. It is set to escalate to $10.83 billion by 2029, with a compound annual growth rate (CAGR) of 5.6%. The resurgence of this market in the forecast period can be associated with the increasing adoption of minimally invasive procedures, growing count of elderly patients, enhanced availability of sophisticated treatment methods, a rising emphasis on patient-centric care, and an increase in the incidence of comorbidities. The forecast period will witness significant trends such as the development of focused therapies, digital health solutions integration, advancements in surgical methods, implementation of 3D imaging for diagnosis, and innovations in patient-centered care structure.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp
Who are the Major Competitors in the Benign Prostatic Hyperplasia Treatment Market Outlook?
Major companies operating in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd.
What Is Fueling Growth in the Benign Prostatic Hyperplasia Treatment Market?
The increasing acceptance of minimally invasive surgical procedures is projected to be a key driver in the expansion of the benign prostatic hyperplasia treatment market in the future. These surgeries, which involve small or no incisions, use specific tools to lessen recovery time, pain, and potential complications. The surge in the use of minimally invasive surgeries can be ascribed to benefits like shorter recuperation periods, minimised discomfort, decreased risk of complications, and superior cosmetic results. Treatment for benign prostatic hyperplasia using these surgical methods offers benefits like faster recovery, lesser chances of complications, effective resolution of symptoms, boosting overall surgical results. An example is from September 2023, where the American Society of Plastic Surgeons (ASPS) revealed that in 2022, around 23,672,269 cosmetic minimally invasive treatments were conducted worldwide. These treatments included neuromodulator injections, lip augmentations, and non-invasive skin tightening. Hence, the growing adoption of minimally invasive surgical procedures is fuelling the growth of the benign prostatic hyperplasia treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21112&type=smp
Which Benign Prostatic Hyperplasia Treatment Market Segments Are Growing the Fastest?
The benign prostatic hyperplasia treatment market covered in this report is segmented –
1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics, Research And Manufacturing
Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy
Which Industry Trends Are Shaping the Future of the Benign Prostatic Hyperplasia Treatment Market?
Key players in the benign prostatic hyperplasia treatment industry are focusing on the creation of novel solutions, for example, minimally invasive procedures, to improve patient results and reduce recovery durations. These methods entail minor or no surgical cuts, thus reducing trauma, discomfort, and risks, while also facilitating a quicker healing process compared to conventional surgical techniques. Take for example, Teleflex Incorporated, a medical device establishment based in the U.S, which introduced the UroLift System for treating benign prostatic hyperplasia in December 2022. Here, tiny permanent implants are used to reposition the enlarged prostate tissue, providing substantial symptom relief without requiring tissue removal, incision, or heating. This outpatient procedure guarantees speedy recovery, maintains sexual functionality, and offers superior symptom relief relative to traditional BPH medications, with side effects typically subsiding within a span of two to four weeks.
Access The Full Report Here:
Which Countries Are Leading the Benign Prostatic Hyperplasia Treatment Market?
North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21112
This Report Delivers Insight On:
1. How big is the benign prostatic hyperplasia treatment market, and how is it changing globally?
2. Who are the major companies in the benign prostatic hyperplasia treatment market, and how are they performing?
3. What are the key opportunities and risks in the benign prostatic hyperplasia treatment market right now?
4. Which products or customer segments are growing the most in the benign prostatic hyperplasia treatment market?
5. What factors are helping or slowing down the growth of the benign prostatic hyperplasia treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
